{"entity":{"type":"insider","cik":"0001288452","url":"/insider/0001288452","json_url":"/insider/0001288452.json","name":"BAY CITY CAPITAL LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":127,"n_filings":34,"first":"2007-04-30","last":"2021-10-26","span_basis":"filed_date"},"name_variants":[{"name":"BAY CITY CAPITAL LLC","source":"filing","n_filings":34,"first_seen":"2007-04-30","last_seen":"2021-10-26"}],"transactions":[{"id":5248426,"accession":"0001104659-21-130027","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-21-130027","line_url":"/filing/0001104659-21-130027#line-3","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":"0001288452","owner_name":"BAY CITY CAPITAL LLC","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":"/insider/0001288452","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":312500.0,"shares_display":"312,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":1129490.0,"shares_owned_after_display":"1,129,490","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-10-26","filed_date":"2021-10-26","scope":"insider"},{"id":2208131,"accession":"0000899243-20-022972","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-022972","line_url":"/filing/0000899243-20-022972#line-3","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":null,"owner_name":"BAY CITY CAPITAL LLC; BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP; Bay City Capital Fund IV, L.P.; Bay City Capital Management IV LLC","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7303.0,"shares_display":"7,303","price_per_share":107.64,"price_display":"107.64","price_state":"stated","total_value":786094.92,"total_display":"786,094.92","total_whole":"786,095","shares_owned_after":42875.0,"shares_owned_after_display":"42,875","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-19","filed_date":"2020-08-19","scope":"insider"},{"id":2208127,"accession":"0000899243-20-022972","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-022972","line_url":"/filing/0000899243-20-022972#line-2","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":null,"owner_name":"BAY CITY CAPITAL LLC; BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP; Bay City Capital Fund IV, L.P.; Bay City Capital Management IV LLC","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10197.0,"shares_display":"10,197","price_per_share":110.03,"price_display":"110.03","price_state":"stated","total_value":1121975.91,"total_display":"1,121,975.91","total_whole":"1,121,976","shares_owned_after":50178.0,"shares_owned_after_display":"50,178","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-18","filed_date":"2020-08-19","scope":"insider"},{"id":2208123,"accession":"0000899243-20-022972","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-022972","line_url":"/filing/0000899243-20-022972#line-1","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":null,"owner_name":"BAY CITY CAPITAL LLC; BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP; Bay City Capital Fund IV, L.P.; Bay City Capital Management IV LLC","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":110.73,"price_display":"110.73","price_state":"stated","total_value":1384125.0,"total_display":"1,384,125.00","total_whole":"1,384,125","shares_owned_after":60375.0,"shares_owned_after_display":"60,375","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-17","filed_date":"2020-08-19","scope":"insider"},{"id":8414109,"accession":"0000899243-19-029139","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-029139","line_url":"/filing/0000899243-19-029139","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":null,"owner_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP; Bay City Capital Management IV LLC; BAY CITY CAPITAL LLC; Bay City Capital Fund IV, L.P.","owner_display_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1200000.0,"shares_display":"1,200,000","price_per_share":105.47,"price_display":"105.47","price_state":"stated","total_value":126564000.0,"total_display":"126,564,000.00","total_whole":"126,564,000","shares_owned_after":4089702.0,"shares_owned_after_display":"4,089,702","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-13","filed_date":"2019-12-13","scope":"insider","n_lines":2},{"id":6010131,"accession":"0001179110-18-009105","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-18-009105","line_url":"/filing/0001179110-18-009105#line-2","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"Kezar Life Sciences, Inc.","issuer_ticker":"KZR","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":"0001288452","owner_name":"BAY CITY CAPITAL LLC","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":"/insider/0001288452","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2250000.0,"total_display":"2,250,000.00","total_whole":"2,250,000","shares_owned_after":622229.0,"shares_owned_after_display":"622,229","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-25","filed_date":"2018-06-28","scope":"insider"},{"id":6513258,"accession":"0001179110-18-008424","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-18-008424","line_url":"/filing/0001179110-18-008424","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001288452","owner_name":"BAY CITY CAPITAL LLC","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":"/insider/0001288452","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":280000.0,"shares_display":"280,000","price_per_share":287.46,"price_display":"287.46","price_state":"stated","total_value":80488800.0,"total_display":"80,488,800.00","total_whole":"80,488,800","shares_owned_after":5264382.0,"shares_owned_after_display":"5,264,382","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-11","filed_date":"2018-06-12","scope":"insider","n_lines":2},{"id":2446913,"accession":"0000899243-16-026077","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-026077","line_url":"/filing/0000899243-16-026077","is_derivative":false,"issuer_cik":"0001037649","issuer_name":"INTERLEUKIN GENETICS INC","issuer_ticker":"ILIU","issuer_name_source":null,"issuer_url":"/issuer/0001037649","owner_cik":null,"owner_name":"Bay City Capital Fund V Co-Investment Fund, L.P.; Bay City Capital Management V LLC; BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.","owner_display_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30181086.0,"shares_display":"30,181,086","price_per_share":0.0994,"price_display":"0.10","price_state":"stated","total_value":2999999.9484,"total_display":"2,999,999.95","total_whole":"3,000,000","shares_owned_after":75800716.0,"shares_owned_after_display":"75,800,716","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-07-29","filed_date":"2016-08-02","scope":"insider","n_lines":2},{"id":3166707,"accession":"0001209191-16-090962","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-090962","line_url":"/filing/0001209191-16-090962","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"Epizyme, Inc.","issuer_ticker":"EPZM","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"Bay City Capital Fund V, L.P.; Bay City Capital Fund V Co-Investment Fund, L.P.; Bay City Capital Management V LLC; BAY CITY CAPITAL LLC","owner_display_name":"Bay City Capital Fund V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":555555.0,"shares_display":"555,555","price_per_share":9.0,"price_display":"9.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":3370562.0,"shares_owned_after_display":"3,370,562","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-01-12","filed_date":"2016-01-12","scope":"insider","n_lines":2},{"id":8169926,"accession":"0000899243-15-001801","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-15-001801","line_url":"/filing/0000899243-15-001801","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"SUNESIS PHARMACEUTICALS INC","issuer_ticker":"SNSS","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":null,"owner_name":"Bay City Capital Fund V Co-Investment Fund, L.P.; BAY CITY CAPITAL LLC; Bay City Capital Management V LLC; Bay City Capital Fund V, L.P.","owner_display_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":635702.0,"shares_display":"635,702","price_per_share":3.46,"price_display":"3.46","price_state":"stated","total_value":2199528.92,"total_display":"2,199,528.92","total_whole":"2,199,529","shares_owned_after":5267598.0,"shares_owned_after_display":"5,267,598","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-07-24","filed_date":"2015-07-28","scope":"insider","n_lines":4},{"id":8284162,"accession":"0001181431-15-008441","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-15-008441","line_url":"/filing/0001181431-15-008441","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"NEVRO CORP","issuer_ticker":"NVRO","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"Bay City Capital Fund IV, L.P.; BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP; Bay City Capital Management IV LLC; BAY CITY CAPITAL LLC","owner_display_name":"Bay City Capital Fund IV, L.P.","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":491835.0,"shares_display":"491,835","price_per_share":47.94,"price_display":"47.94","price_state":"stated","total_value":23578569.9,"total_display":"23,578,569.90","total_whole":"23,578,570","shares_owned_after":1688976.0,"shares_owned_after_display":"1,688,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-08","filed_date":"2015-06-17","scope":"insider","n_lines":2},{"id":6421264,"accession":"0001209191-14-077958","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-14-077958","line_url":"/filing/0001209191-14-077958","is_derivative":false,"issuer_cik":"0001037649","issuer_name":"INTERLEUKIN GENETICS INC","issuer_ticker":"ILIU","issuer_name_source":null,"issuer_url":"/issuer/0001037649","owner_cik":null,"owner_name":"Bay City Capital Fund V, L.P.; Bay City Capital Fund V Co-Investment Fund, L.P.; Bay City Capital Management V LLC; BAY CITY CAPITAL LLC","owner_display_name":"Bay City Capital Fund V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":26491952.0,"shares_display":"26,491,952","price_per_share":0.1003,"price_display":"0.10","price_state":"stated","total_value":2657142.7856,"total_display":"2,657,142.79","total_whole":"2,657,143","shares_owned_after":46184016.0,"shares_owned_after_display":"46,184,016","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-12-23","filed_date":"2014-12-24","scope":"insider","n_lines":2},{"id":6669388,"accession":"0001140361-14-037654","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-14-037654","line_url":"/filing/0001140361-14-037654","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"Dermira, Inc.","issuer_ticker":"DERM","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"Bay City Capital Management V LLC; BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.; Bay City Capital Fund V Co-Investment Fund, L.P.","owner_display_name":"Bay City Capital Management V LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":69112.0,"shares_display":"69,112","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":1105792.0,"total_display":"1,105,792.00","total_whole":"1,105,792","shares_owned_after":3441075.0,"shares_owned_after_display":"3,441,075","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-10-08","filed_date":"2014-10-08","scope":"insider","n_lines":2},{"id":6520150,"accession":"0001181431-14-030525","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001181431-14-030525","line_url":"/filing/0001181431-14-030525","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"SUNESIS PHARMACEUTICALS INC","issuer_ticker":"SNSS","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":null,"owner_name":"Bay City Capital Management V LLC; Bay City Capital Fund V Co-Investment Fund, L.P.; BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.","owner_display_name":"Bay City Capital Management V LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200000.0,"shares_display":"200,000","price_per_share":7.8851,"price_display":"7.89","price_state":"stated","total_value":1577020.0,"total_display":"1,577,020.00","total_whole":"1,577,020","shares_owned_after":4597427.0,"shares_owned_after_display":"4,597,427","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-28","filed_date":"2014-08-29","scope":"insider","n_lines":2},{"id":6520146,"accession":"0001181431-14-030525","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-14-030525","line_url":"/filing/0001181431-14-030525","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"SUNESIS PHARMACEUTICALS INC","issuer_ticker":"SNSS","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":null,"owner_name":"Bay City Capital Management V LLC; Bay City Capital Fund V Co-Investment Fund, L.P.; BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.","owner_display_name":"Bay City Capital Management V LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100700.0,"shares_display":"100,700","price_per_share":8.163,"price_display":"8.16","price_state":"stated","total_value":822014.1,"total_display":"822,014.10","total_whole":"822,014","shares_owned_after":4795570.0,"shares_owned_after_display":"4,795,570","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-27","filed_date":"2014-08-29","scope":"insider","n_lines":2},{"id":7094535,"accession":"0001209191-14-054864","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-14-054864","line_url":"/filing/0001209191-14-054864","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"Epizyme, Inc.","issuer_ticker":"EPZM","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"Bay City Capital Fund V, L.P.; Bay City Capital Management V LLC; BAY CITY CAPITAL LLC; Bay City Capital Fund V Co-Investment Fund, L.P.","owner_display_name":"Bay City Capital Fund V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, par value $0.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200000.0,"shares_display":"200,000","price_per_share":35.139,"price_display":"35.14","price_state":"stated","total_value":7027800.0,"total_display":"7,027,800.00","total_whole":"7,027,800","shares_owned_after":2829136.0,"shares_owned_after_display":"2,829,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-26","filed_date":"2014-08-28","scope":"insider","n_lines":2},{"id":6493826,"accession":"0001209191-14-054308","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-14-054308","line_url":"/filing/0001209191-14-054308","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"Epizyme, Inc.","issuer_ticker":"EPZM","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.; Bay City Capital Management V LLC; Bay City Capital Fund V Co-Investment Fund, L.P.","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, par value $0.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200000.0,"shares_display":"200,000","price_per_share":35.13901275,"price_display":"35.14","price_state":"stated","total_value":7027802.55,"total_display":"7,027,802.55","total_whole":"7,027,803","shares_owned_after":2830019.0,"shares_owned_after_display":"2,830,019","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-25","filed_date":"2014-08-25","scope":"insider","n_lines":4},{"id":6493818,"accession":"0001209191-14-054308","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-14-054308","line_url":"/filing/0001209191-14-054308","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"Epizyme, Inc.","issuer_ticker":"EPZM","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.; Bay City Capital Management V LLC; Bay City Capital Fund V Co-Investment Fund, L.P.","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, par value $0.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":128000.0,"shares_display":"128,000","price_per_share":32.4591,"price_display":"32.46","price_state":"stated","total_value":4154764.8,"total_display":"4,154,764.80","total_whole":"4,154,765","shares_owned_after":3027790.0,"shares_owned_after_display":"3,027,790","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-22","filed_date":"2014-08-25","scope":"insider","n_lines":2},{"id":6493815,"accession":"0001209191-14-054308","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-14-054308","line_url":"/filing/0001209191-14-054308","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"Epizyme, Inc.","issuer_ticker":"EPZM","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.; Bay City Capital Management V LLC; Bay City Capital Fund V Co-Investment Fund, L.P.","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, par value $0.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":38666.0,"shares_display":"38,666","price_per_share":33.0352,"price_display":"33.04","price_state":"stated","total_value":1277339.0432,"total_display":"1,277,339.04","total_whole":"1,277,339","shares_owned_after":3154119.0,"shares_owned_after_display":"3,154,119","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-21","filed_date":"2014-08-25","scope":"insider","n_lines":2},{"id":6342755,"accession":"0001181431-14-029004","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001181431-14-029004","line_url":"/filing/0001181431-14-029004","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"SUNESIS PHARMACEUTICALS INC","issuer_ticker":"SNSS","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":null,"owner_name":"BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.; Bay City Capital Management V LLC; Bay City Capital Fund V Co-Investment Fund, L.P.","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37100.0,"shares_display":"37,100","price_per_share":6.7717,"price_display":"6.77","price_state":"stated","total_value":251230.07,"total_display":"251,230.07","total_whole":"251,230","shares_owned_after":4895081.0,"shares_owned_after_display":"4,895,081","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-12","filed_date":"2014-08-12","scope":"insider","n_lines":2},{"id":6342750,"accession":"0001181431-14-029004","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001181431-14-029004","line_url":"/filing/0001181431-14-029004","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"SUNESIS PHARMACEUTICALS INC","issuer_ticker":"SNSS","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":null,"owner_name":"BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.; Bay City Capital Management V LLC; Bay City Capital Fund V Co-Investment Fund, L.P.","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31600.0,"shares_display":"31,600","price_per_share":6.902,"price_display":"6.90","price_state":"stated","total_value":218103.2,"total_display":"218,103.20","total_whole":"218,103","shares_owned_after":4932078.0,"shares_owned_after_display":"4,932,078","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-11","filed_date":"2014-08-12","scope":"insider","n_lines":2},{"id":6342744,"accession":"0001181431-14-029004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-14-029004","line_url":"/filing/0001181431-14-029004","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"SUNESIS PHARMACEUTICALS INC","issuer_ticker":"SNSS","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":null,"owner_name":"BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.; Bay City Capital Management V LLC; Bay City Capital Fund V Co-Investment Fund, L.P.","owner_display_name":"BAY CITY CAPITAL LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":675000.0,"shares_display":"675,000","price_per_share":6.6201,"price_display":"6.62","price_state":"stated","total_value":4468567.5,"total_display":"4,468,567.50","total_whole":"4,468,568","shares_owned_after":4975709.0,"shares_owned_after_display":"4,975,709","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-08","filed_date":"2014-08-12","scope":"insider","n_lines":2},{"id":6410275,"accession":"0001209191-14-009595","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-14-009595","line_url":"/filing/0001209191-14-009595","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"Epizyme, Inc.","issuer_ticker":"EPZM","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"Bay City Capital Management V LLC; BAY CITY CAPITAL LLC; Bay City Capital Fund V Co-Investment Fund, L.P.; Bay City Capital Fund V, L.P.","owner_display_name":"Bay City Capital Management V LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, par value $0.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":466667.0,"shares_display":"466,667","price_per_share":29.25,"price_display":"29.25","price_state":"stated","total_value":13650009.75,"total_display":"13,650,009.75","total_whole":"13,650,010","shares_owned_after":3200789.0,"shares_owned_after_display":"3,200,789","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-02-10","filed_date":"2014-02-12","scope":"insider","n_lines":2},{"id":5538507,"accession":"0001209191-13-031138","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-13-031138","line_url":"/filing/0001209191-13-031138","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"Epizyme, Inc.","issuer_ticker":"EPZM","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"Bay City Capital Management V LLC; BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.; Bay City Capital Fund V Co-Investment Fund, L.P.","owner_display_name":"Bay City Capital Management V LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":166666.0,"shares_display":"166,666","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2499990.0,"total_display":"2,499,990.00","total_whole":"2,499,990","shares_owned_after":3655612.0,"shares_owned_after_display":"3,655,612","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-06-05","filed_date":"2013-06-07","scope":"insider","n_lines":2},{"id":4736505,"accession":"0001181431-13-031712","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001181431-13-031712","line_url":"/filing/0001181431-13-031712","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"HYPERION THERAPEUTICS INC","issuer_ticker":"HPTX","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"Bay City Capital Management V LLC; Bay City Capital Fund V Co-Investment Fund, L.P.; BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.","owner_display_name":"Bay City Capital Management V LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5366.0,"shares_display":"5,366","price_per_share":21.0,"price_display":"21.00","price_state":"stated","total_value":112686.0,"total_display":"112,686.00","total_whole":"112,686","shares_owned_after":2260990.0,"shares_owned_after_display":"2,260,990","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-30","filed_date":"2013-05-30","scope":"insider","n_lines":2},{"id":4736491,"accession":"0001181431-13-031712","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-13-031712","line_url":"/filing/0001181431-13-031712#line-2","is_derivative":false,"issuer_cik":"0001288452","issuer_name":"HYPERION THERAPEUTICS INC","issuer_ticker":"HPTX","issuer_name_source":null,"issuer_url":"/issuer/0001288452","owner_cik":null,"owner_name":"Bay City Capital Management V LLC; Bay City Capital Fund V Co-Investment Fund, L.P.; BAY CITY CAPITAL LLC; Bay City Capital Fund V, L.P.","owner_display_name":"Bay City Capital Management V LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11776.0,"shares_display":"11,776","price_per_share":21.08,"price_display":"21.08","price_state":"stated","total_value":248238.08,"total_display":"248,238.08","total_whole":"248,238","shares_owned_after":2266256.0,"shares_owned_after_display":"2,266,256","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-28","filed_date":"2013-05-30","scope":"insider"}],"collapsed":true,"next_cursor":"2013-05-28|4736491","ledger_fault":false,"count":{"value":4,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":2,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":4},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001840233","name":"Xilio Therapeutics, Inc.","url":"/issuer/0001840233","role":"Ten percent owner","n_filings":1,"first_seen":"2021-10-26","last_seen":"2021-10-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001157601","name":"MADRIGAL PHARMACEUTICALS, INC.","url":"/issuer/0001157601","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2018-06-12","last_seen":"2020-08-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001645666","name":"Kezar Life Sciences, Inc.","url":"/issuer/0001645666","role":"Ten percent owner","n_filings":1,"first_seen":"2018-06-28","last_seen":"2018-06-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001037649","name":"INTERLEUKIN GENETICS INC","url":"/issuer/0001037649","role":"Ten percent owner","n_filings":2,"first_seen":"2014-12-24","last_seen":"2016-08-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001571498","name":"Epizyme, Inc.","url":"/issuer/0001571498","role":"Ten percent owner","n_filings":5,"first_seen":"2013-06-07","last_seen":"2016-01-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001061027","name":"SUNESIS PHARMACEUTICALS INC","url":"/issuer/0001061027","role":"Ten percent owner","n_filings":4,"first_seen":"2010-07-01","last_seen":"2015-07-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001444380","name":"NEVRO CORP","url":"/issuer/0001444380","role":"Other","n_filings":1,"first_seen":"2015-06-17","last_seen":"2015-06-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001557883","name":"Dermira, Inc.","url":"/issuer/0001557883","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2014-10-08","last_seen":"2014-10-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001386858","name":"HYPERION THERAPEUTICS INC","url":"/issuer/0001386858","role":"Ten percent owner","n_filings":2,"first_seen":"2013-05-21","last_seen":"2013-05-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001371217","name":"EnteroMedics Inc","url":"/issuer/0001371217","role":"Ten percent owner","n_filings":8,"first_seen":"2007-11-19","last_seen":"2011-09-26"},{"type":"issuer","type_label":"ISSUER","cik":"0000755806","name":"PONIARD PHARMACEUTICALS, INC.","url":"/issuer/0000755806","role":"Ten percent owner","n_filings":5,"first_seen":"2007-04-30","last_seen":"2007-08-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001003929","name":"VIA Pharmaceuticals, Inc.","url":"/issuer/0001003929","role":"Ten percent owner","n_filings":1,"first_seen":"2007-08-08","last_seen":"2007-08-08"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001288452","retrieved_at":"2026-08-23T03:13:12+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}